Evidence map›Paper›PMID 30065933›Full record

ArticleBioMed research international2018

PATRI, a Genomics Data Integration Tool for Biomarker Discovery.

G Ukmar, G E M Melloni, L Raddrizzani, P Rossi, S Di Bella, M R Pirchio, M Vescovi, A Leone, M Callari, M Cesarini and 6 more

Abstract read
In one paragraph

Article in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Emerging targets in cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

G UkmarNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.ORCID 0000-0002-1149-2587
G E M MelloniUniversity of Milano Bicocca, Milano, Italy.ORCID 0000-0001-6371-1334
L RaddrizzaniNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.ORCID 0000-0001-8996-1702
P RossiIcona Srl, Cinisello Balsamo, Italy.
S Di BellaNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.ORCID 0000-0001-7161-303X
M R PirchioIcona Srl, Cinisello Balsamo, Italy.
M VescoviParametric Design Biotech, Gessate, Italy.
A LeoneNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.
M CallariFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.ORCID 0000-0001-5239-0918
M CesariniUniversity of Milano Bicocca, Milano, Italy.
A SomaschiniNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.
G Della VedovaUniversity of Milano Bicocca, Milano, Italy.ORCID 0000-0001-5584-3089
M G DaidoneFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
M PettenellaParametric Design Biotech, Gessate, Italy.
A IsacchiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.
R BosottiNMS Oncology, Nerviano Medical Sciences Srl, Nerviano, Italy.ORCID 0000-0002-5467-6212

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The availability of genomic datasets in association with clinical, phenotypic, and drug sensitivity information represents an invaluable source for potential therapeutic applications, supporting the identification of new drug sensitivity biomarkers and pharmacological targets. Drug discovery and precision oncology can largely benefit from the integration of treatment molecular discriminants obtained from cell line models and clinical tumor samples; however this task demands comprehensive analysis approaches for the discovery of underlying data connections. Here we introduce PATRI (Platform for the Analysis of TRanslational Integrated data), a standalone tool accessible through a user-friendly graphical interface, conceived for the identification of treatment sensitivity biomarkers from user-provided genomics data, associated with information on sample characteristics. PATRI streamlines a translational analysis workflow: first, baseline genomics signatures are statistically identified, differentiating treatment sensitive from resistant preclinical models; then, these signatures are used for the prediction of treatment sensitivity in clinical samples, via random forest categorization of clinical genomics datasets and statistical evaluation of the relative phenotypic features. The same workflow can also be applied across distinct clinical datasets. The ease of use of the PATRI tool is illustrated with validation analysis examples, performed with sensitivity data for drug treatments with known molecular discriminants.

Indexed as

GenomicsNeoplasmsPrecision MedicineBiomarkersHumansProteomicsBiomarkers

Identifiers

PMID30065933
PMCPMC6051285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.